(CercleFinance.com) – Sandoz indicates that it has finalized, ahead of schedule, the acquisition of the American biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences, in accordance with the agreement last January for a purchase price of 170 millions of dollars.
“With the addition of Cimerli to our existing ophthalmology franchise, we can offer even more treatment options to American patients suffering from vision impairment and loss,” comments Keren Haruvi, President of Sandoz North America.
A biosimilar to Lucentis, Cimerli is indicated for the treatment of certain retinal diseases that, if left untreated, can lead to vision loss, which ranks among the top 10 causes of disability in the United States.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
This is a Smartvoice article: see legal notices